ESSA Pharma Inc
EPIX1.880USD
0.000
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
83.45MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über ESSA Pharma Inc Unternehmen
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Unternehmensinformationen
BörsenkürzelEPIX
Name des UnternehmensESSA Pharma Inc
IPO-datumFeb 22, 2021
CEODr. David Ross Parkinson, M.D.
Anzahl der mitarbeiter35
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 22
Addresse999 West Broadway, Suite 720
StadtVANCOUVER
BörseNASDAQ Capital Market Consolidated
LandCanada
PostleitzahlV5Z 1K5
Telefon17783310962
Websitehttps://www.essapharma.com/
BörsenkürzelEPIX
IPO-datumFeb 22, 2021
CEODr. David Ross Parkinson, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Richard M. Glickman, LL.D.
Dr. Richard M. Glickman, LL.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
51.70K
-14.06%
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
33.59K
+0.75%
Mr. Scott Requadt
Mr. Scott Requadt
Independent Director
Independent Director
30.00K
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.78K
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
5.12K
--
Ms. Marella Thorell
Ms. Marella Thorell
Independent Director
Independent Director
2.88K
--
Mr. Franklin M. Berger
Mr. Franklin M. Berger
Independent Director
Independent Director
--
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Dr. David Ross Parkinson, M.D.
Dr. David Ross Parkinson, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Alex Martin
Mr. Alex Martin
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Richard M. Glickman, LL.D.
Dr. Richard M. Glickman, LL.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
51.70K
-14.06%
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
33.59K
+0.75%
Mr. Scott Requadt
Mr. Scott Requadt
Independent Director
Independent Director
30.00K
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.78K
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
5.12K
--
Ms. Marella Thorell
Ms. Marella Thorell
Independent Director
Independent Director
2.88K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BVF Partners L.P.
19.71%
Soleus Capital Management, L.P.
9.83%
Tang Capital Management, LLC
9.69%
BML Capital Management LLC
9.51%
Morgan Stanley & Co. LLC
9.46%
Other
41.80%
Aktionäre
Aktionäre
Anteil
BVF Partners L.P.
19.71%
Soleus Capital Management, L.P.
9.83%
Tang Capital Management, LLC
9.69%
BML Capital Management LLC
9.51%
Morgan Stanley & Co. LLC
9.46%
Other
41.80%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
46.19%
Investment Advisor
13.36%
Research Firm
11.99%
Corporation
3.77%
Investment Advisor/Hedge Fund
2.45%
Individual Investor
2.24%
Venture Capital
0.05%
Other
19.93%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
91
33.44M
75.34%
-17.34M
2025Q1
96
33.48M
75.44%
-17.56M
2024Q4
101
34.20M
77.05%
-15.63M
2024Q3
97
36.44M
82.10%
-7.65M
2024Q2
110
36.54M
82.36%
-10.99M
2024Q1
138
36.33M
81.91%
-11.35M
2023Q4
143
35.77M
81.03%
-12.57M
2023Q3
161
36.59M
82.99%
-18.42M
2023Q2
177
36.37M
82.51%
-21.24M
2023Q1
185
36.21M
82.14%
-19.98M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BVF Partners L.P.
8.75M
19.71%
--
--
Apr 09, 2025
Soleus Capital Management, L.P.
2.26M
5.1%
--
--
Apr 23, 2025
Tang Capital Management, LLC
4.30M
9.69%
--
--
Mar 31, 2025
BML Capital Management LLC
4.22M
9.51%
--
--
Apr 24, 2025
Morgan Stanley & Co. LLC
4.20M
9.46%
+10.76K
+0.26%
Mar 31, 2025
Opaleye Management Inc.
2.21M
4.98%
--
--
Mar 31, 2025
Pfizer Inc
1.68M
3.77%
--
--
Mar 31, 2025
Altium Capital Management LP
1.05M
2.37%
-377.63K
-26.44%
Mar 31, 2025
Berger (Franklin Milan)
784.40K
1.77%
--
--
Jan 08, 2025
BofA Global Research (US)
698.27K
1.57%
-114.04K
-14.04%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Avantis US Small Cap Equity ETF
0%
Avantis US Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
